MiRNAs and Their Interference with the Main Molecular Mechanisms Responsible for Drug Resistance in Pancreatic Cancer

Garajová I, Giovannetti E, Caponi S, van Zweeden A, Peters GJ.

Curr Pharmacol Rep (2015) 1:223–233

continue reading →

Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells

Leon LG, Gemelli M, Sciarrillo R, Avan A, Funel N, Giovannetti E

Curr Drug Targets. 2014;15(14):1331-40

continue reading →

New strategies and applications for Drugs Targeting EGFR and C-Met

Giovannetti E, Leon LG.

Curr Drug Targets. 2014;15(14):1261-2

continue reading →

AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients

Avan A, Avan A, Le Large TY, Mambrini A, Funel N, Maftouh M, Ghayour-Mobarhan M, Cantore M, Boggi U, Peters GJ, Pacetti P, Giovannetti E
PLoS One. 2014 Sep 19;9(9):e108057. doi: 10.1371/journal.pone.0108057. eCollection 2014

continue reading →

Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer

Garajova I, Le Large TY, Frampton AE, Rolfo C, Voortman J, Giovannetti E
BioMed Research International 2014;678401

continue reading →

Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma

Maftouh M, Belo AI, Avan A, Funel N, Peters GJ, Giovannetti E,* van Die I.*
Oncotarget 2014; 30;5(14):5335-49 (*these authors equally contributed to the study)

continue reading →

Impact of MicroRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer

Rolfo C, Fanale D, Hong DS, Tsimberidou AM, Piha-Paul SA, Pauwels P, Van Meerbeeck JP, Caruso S, Bazan V, Cicero G, Russo A, Giovannetti E
Curr Pharm Biotechnol. 2014; 15(5):475-85

continue reading →

miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells

Maftouh M, Avan A, Funel N, Frampton AE, Fiuji H, Pelliccioni S, Castellano L, Galla V, Peters GJ, Giovannetti E
Nucleosides Nucleotides Nucleic Acids. 2014;33(4-6):384-93

continue reading →

SNPs in PI3K–PTEN–mTOR and Brain Metastases in NSCLC – Letter

Avan A, Maftouh M, Avan A, Tibaldi C, Zucali PA, Giovannetti E
Clin Cancer Res 2014; 20(13):3623-4

A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients

Maftouh M, Avan A, Funel N, Paolicchi E, Vasile E, Pacetti P, Vaccaro V, Faviana P, Campani D, Caponi S, Mambrini A, Boggi U, Cantore M, Milella M, Peters GJ, Reni M, Giovannetti E
Pharmacogenomics 2014;15:609-18. 1

continue reading →

Lactate dehydrogenase acetylation adds another piece to the puzzle of metabolic reprogramming in pancreatic cancer

Sciarrillo R, Minutolo F, Peters GJ, Giovannetti E
Translational Gastrointestinal Cancer. Vol 3, No 2 (April 2014)

Link: www.amepc.org/tgc/article/view/3706/4598
Free full PDF text: click here

CYB5A and autophagy-mediated cell death in pancreatic cancer

Giovannetti E, Giaccone G.
Autophagy 2014;10:697-8

continue reading →

CYB5A role in pancreatic cancer prognosis and autophagy modulation

Giovannetti E,* Wang Q,* Avan A, Funel N, Lagerweij T, Lee JH, Caretti V, van der Velde A, Boggi U, Wang Y, Vasile E, Peters GJ, Wurdinger T, Giaccone G
JNCI – J Natl Cancer Inst. 2014;106(1):djt346. (*these authors equally contributed to the study)

continue reading →

All the publications authored by Dr. Giovannetti (until december 2019)


ORCID ID orcid.org/0000-0002-7565-7504
(see also: www.scopus.com)
continue reading →

Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma

Avan A, Caretti V, Funel N, Galvani E, Maftouh M, Honeywell RJ, Lagerweij T, Van Tellingen O, Campani D, Fuchs D, Verheul HM, Schuurhuis GJ, Boggi U, Peters GJ, Würdinger T, Giovannetti E
Cancer Res. 2013 Nov 15;73(22):6745-56

continue reading →

MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity

Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Vasile E, Leon LG, Pollina LE, Groen A, Falcone A, Danesi R, Campani D, Verheul HM, Boggi U
Cancer Res. 2010 Jun 1;70(11):4528-38

continue reading →

Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, Di Marsico R, Antonuzzo A, Orlandini C, Ricciardi S, Del Tacca M, Peters GJ, Falcone A, Danesi R
Clin Cancer Res. 2008 Mar 15;14(6):1797-803

continue reading →

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine

Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del Chiaro M, Iannopollo M, Bevilacqua G, Mosca F, Danesi R
Cancer Res. 2006 Apr 1;66(7):3928-35

continue reading →

Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non–small-cell lung cancer cells

Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R
Mol Pharmacol. 2005 Jul;68(1):110-8

continue reading →